AB Science
Press release/News aggregator
AB Science est une entreprise française du secteur des biotechnologies et de la pharmacie fondée en 2001, spécialisée dans la recherche, le développement et la commercialisation de médicaments utilisés dans le traitement des tumeurs cancéreuses, des maladies inflammatoires et des maladies neurodégénératives. Source
Actions
Media Outlet details
| Scope | National, Consumer |
|---|---|
| Language | English, French |
| Country | France |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
Recent Articles
Search ArticlesAB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 2026
17/08/2026 – AB Science today announces the successful settlement and delivery of the securities issued as part of its capital increases subscribed to by a limited number of investors and announced on August 10, 2026
AB Science annonce le succès du règlement-livraison des titres émis dans le cadre de son placement privé de 14,2 millions d’euros annoncé le 10 aout 2026
Masitinib and AB8939 - Two compounds with breakthrough mechanism of action
AB Science announces the successful completion of capital increases of a total gross amount of EUR 14.2 million
AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs
AB Science annonce le succès d’augmentations de capital d’un montant brut total de 14,2 millions d’euros
Masitinib and AB8939 - Two compounds with breakthrough mechanism of action
Webconference presentation on masitinib + isoquercetin in COVID-19
AB Science to present results from its AB07002 study
AB Science to present results from its AB07002 study
AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs
AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs
10/07/2026 – AB Science today provides an update on its clinical development program and announces the discontinuation of certain non-priority clinical studies in order to focus on two clinical programs, the AB8939 program for AML and the masitinib program for ALS
AB Science fait le point sur son programme clinique avec l’arrêt de certaines études cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques
10/07/2026 – AB Science fait aujourd’hui le point sur son programme de développement clinique et annonce l’arrêt de certaines études clinique non prioritaires, en vue de se concentrer sur deux programmes cliniques, le programme AB8939 dans la LMA et le programme masitinib dans la SLA
AB Science’s Board of Directors is restructuring its governance to usher in a new phase in the company’s development
08/07/2026 – Appointment of Stéphane LEDERMANN as Chairman and Chief Executive Officer
Le Conseil d’administration d’AB Science fait évoluer la gouvernance afin d’engager une nouvelle étape du développement de la société
Masitinib and AB8939 - Two compounds with breakthrough mechanism of action